Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Day: March 2, 2026

Oncology News

Oncology Video Recap—March 2, 2026

This biweekly Oncology and Biopharma Regulatory Watch video recap highlights…

Onco_background

Oncology Today—March 2, 2026

This week’s Oncology update highlights major regulatory approvals,…

Hematology

Hematology Today—March 2, 2026

This is a weekly update in Hematology, covering key regulatory actions,…

Artificial_Intelligence

AI in Healthcare and Digital Health Today—March 2, 2026

This week’s AI in Healthcare and Digital Health update highlights…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”

Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”…

by Timos Papagatsias

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Neuroscience Today—April 8, 2026
Immunology Today—April 8, 2026
Obesity Today—April 7, 2026
Endocrinology Today—April 7, 2026
Lucid Diligence Brief: Anthropic acquires Coefficient Bio

Tags

AAV-based gene therapies adaptive design AI for Science American Academy of Pediatrics American Society of Clinical Oncology Biologic therapies Bispecific antibody therapy cancer care cancer vaccines clinicaltrials competitive advantage CVC datasecurity digital health innovation digital pill drug development Elismetrep fair pricing FDA oncology approvals Gene therapy innovation Global hematology market Global neuroscience market google ventures HeartFlow In vivo CRISPR editing mental health Obesity strategy Ovarian Ageing Pain patient centricity peptibody mRNA therapy Population Health Public health market trends Recessive dystrophic epidermolysis bullosa Reproductive health therapies Respiratory drug pipeline Rigel Pharmaceuticals Rybrevant FASPRO Sasineprocel Severe Infections T-cell engagers Tecvayli TNFα US health crisis VOICE ASSISTANT

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Neuroscience Today—April 8, 2026
Immunology Today—April 8, 2026
Obesity Today—April 7, 2026
Endocrinology Today—April 7, 2026
Lucid Diligence Brief: Anthropic acquires Coefficient Bio

TAGS

AAV-based gene therapies adaptive design AI for Science American Academy of Pediatrics American Society of Clinical Oncology Biologic therapies Bispecific antibody therapy cancer care cancer vaccines clinicaltrials competitive advantage CVC datasecurity digital health innovation digital pill drug development Elismetrep fair pricing FDA oncology approvals Gene therapy innovation Global hematology market Global neuroscience market google ventures HeartFlow In vivo CRISPR editing mental health Obesity strategy Ovarian Ageing Pain patient centricity peptibody mRNA therapy Population Health Public health market trends Recessive dystrophic epidermolysis bullosa Reproductive health therapies Respiratory drug pipeline Rigel Pharmaceuticals Rybrevant FASPRO Sasineprocel Severe Infections T-cell engagers Tecvayli TNFα US health crisis VOICE ASSISTANT

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy